Automated Reinforcement Management Systems, Phase II

ConditionAlcohol Use Disorder

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-70

SponsorWashington State University

About this trial

The Automated Reinforcement Management Systems Phase II (ARMS II) study is a phase II trial is a randomized controlled, non-medicated assisted trial to determine the effectiveness of Contingency Management (CM) treatment for reducing alcohol drinking among adults who want to quit or reduce their alcohol consumption.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18-70 years

Have consumed 3 or more drinks in once occasion 4 or more times in the previous 30 days 3

Have the ability to read and speak English

Have the ability to provide written informed consent

Disqualifiers

Severe alcohol use disorder that our medical staff deems too risky for safe participation;

Significant risk of dangerous alcohol withdrawal, defined as history of seizure due to alcohol withdrawal in the last 12 months and/or expression of concern by the participant about dangerous withdrawal

Anyone aged 71 or older.

Anyone with a suicide attempt in the last 2 years.

Trial design

Design model

Parallel

Treatments tested in this trial

Contingency Management
Behavioral
Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.

Treatment groups

125 Participants

are divided into 2 treatment groups

Group A: Contingency Management + Treatment As UsualExperimental treatment 1 intervention

Group B: Non-Contingent Management + Treatment As UsualNo intervention 0 interventions

Trial outcomes

Primary outcomes

Change in days abstinent

Increase in days abstinent as verified through three consecutive negative breathalyzer samples submitted at designated time slots over a period of 12 hours.

Time frame

45 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Washington State University

Lead sponsor

Managed Health Connections

Collaborator

Source ClinicalTrials.gov

Apply now